KPTI - カリョファ―ム・セラピュ―ティクス (Karyopharm Therapeutics Inc.)

KPTIのニュース

   Karyopharm's selinexor shows promising results in COVID-19 and Low LDH/DD (NASDAQ:KPTI)  2020/10/06 12:48:31 Seeking Alpha
Karyopharm Therapeutics (NASDAQ:KPTI) presents data from a Phase 2 clinical study evaluating low dose oral selinexor in hospitalized patients with severe C
   Oncology to COVID-19: Karyopharm (KPTI) CEO on what’s ahead  2020/08/07 19:56:43 AlphaStreet
The oncology research space has become rather crowded these days, with numerous clinical-level companies cropping up with novel technologies. While these offer a lot of scope for speculative trading, finding promising companies in the oncology space has become rather cumbersome. A key criterion while choosing from these biopharma companies should be picking the ones that […]
   The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings  2020/08/02 15:08:50 Benzinga
Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts. COVID-19 news flow continued to pour in, with big pharma tie-ups flaunting positive tidings. In the biggest ever coronavirus funding deal, the Sanofi SA (NASDAQ: SNY ) GlaxoSmithKline plc (NYSE: GSK ) won a joint $2.1 billion U.S. federal funding award. Here're the key catalysts for the unfolding week: Conferences 72nd National Hemophilia Foundation's Annual Bleeding Disorders Meeting 2020 (virtual meeting): Aug. 1-8 PDUFA Dates FDA is scheduled to rule on DBV TECHNOLOGIE/S' ADR (NASDAQ: DBVT ) Viaskin peanut allergy patch Wednesday. However, cancellation of the Adcom meeting scheduled May 15 has poured cold water on the prospects of an approval coming through. Trevena Inc (NASDAQ: TRVN ) has a tryst with the FDA Friday, with respect to the NDA for its pain drug oleceridine, which was once rejected by the agency on the premise of inadequacy of clinical data.
   U.S. Food and Drug Administration Accepts Karyopharm’s Supplemental New Drug Application for XPOVIO® (selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Line of Therapy  2020/07/20 11:00:00 GlobeNewswire
NEWTON, Mass., July 20, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced…
   Karyopharm sees Q2 Xpovio sales of $18.5M (NASDAQ:KPTI)  2020/07/14 11:43:03 Seeking Alpha
Karyopharm Therapeutics (NASDAQ:KPTI) expects preliminary Q2 net product sales for XPOVIO (selinexor) to be ~$18.5M, (+15% Y/Y), topping Bloomberg average
   Oncology to COVID-19: Karyopharm (KPTI) CEO on what’s ahead  2020/08/07 19:56:43 AlphaStreet
The oncology research space has become rather crowded these days, with numerous clinical-level companies cropping up with novel technologies. While these offer a lot of scope for speculative trading, finding promising companies in the oncology space has become rather cumbersome. A key criterion while choosing from these biopharma companies should be picking the ones that […]
   The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings  2020/08/02 15:08:50 Benzinga
Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts. COVID-19 news flow continued to pour in, with big pharma tie-ups flaunting positive tidings. In the biggest ever coronavirus funding deal, the Sanofi SA (NASDAQ: SNY ) GlaxoSmithKline plc (NYSE: GSK ) won a joint $2.1 billion U.S. federal funding award. Here're the key catalysts for the unfolding week: Conferences 72nd National Hemophilia Foundation's Annual Bleeding Disorders Meeting 2020 (virtual meeting): Aug. 1-8 PDUFA Dates FDA is scheduled to rule on DBV TECHNOLOGIE/S' ADR (NASDAQ: DBVT ) Viaskin peanut allergy patch Wednesday. However, cancellation of the Adcom meeting scheduled May 15 has poured cold water on the prospects of an approval coming through. Trevena Inc (NASDAQ: TRVN ) has a tryst with the FDA Friday, with respect to the NDA for its pain drug oleceridine, which was once rejected by the agency on the premise of inadequacy of clinical data.
   U.S. Food and Drug Administration Accepts Karyopharm’s Supplemental New Drug Application for XPOVIO® (selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Line of Therapy  2020/07/20 11:00:00 GlobeNewswire
NEWTON, Mass., July 20, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced…
   Karyopharm sees Q2 Xpovio sales of $18.5M (NASDAQ:KPTI)  2020/07/14 11:43:03 Seeking Alpha
Karyopharm Therapeutics (NASDAQ:KPTI) expects preliminary Q2 net product sales for XPOVIO (selinexor) to be ~$18.5M, (+15% Y/Y), topping Bloomberg average
   Karyopharm Announces Preliminary Unaudited Second Quarter Product Sales for XPOVIO® (selinexor)  2020/07/14 11:00:00 GlobeNewswire
-- Preliminary Unaudited XPOVIO Net Product Sales of Approximately $18.5 Million for the Second Quarter 2020 -- -- Strongest Quarterly XPOVIO Sales Since…
   Oncology to COVID-19: Karyopharm (KPTI) CEO on what’s ahead  2020/08/07 19:56:43 AlphaStreet
The oncology research space has become rather crowded these days, with numerous clinical-level companies cropping up with novel technologies. While these offer a lot of scope for speculative trading, finding promising companies in the oncology space has become rather cumbersome. A key criterion while choosing from these biopharma companies should be picking the ones that […]
   The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings  2020/08/02 15:08:50 Benzinga
Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts. COVID-19 news flow continued to pour in, with big pharma tie-ups flaunting positive tidings. In the biggest ever coronavirus funding deal, the Sanofi SA (NASDAQ: SNY ) GlaxoSmithKline plc (NYSE: GSK ) won a joint $2.1 billion U.S. federal funding award. Here're the key catalysts for the unfolding week: Conferences 72nd National Hemophilia Foundation's Annual Bleeding Disorders Meeting 2020 (virtual meeting): Aug. 1-8 PDUFA Dates FDA is scheduled to rule on DBV TECHNOLOGIE/S' ADR (NASDAQ: DBVT ) Viaskin peanut allergy patch Wednesday. However, cancellation of the Adcom meeting scheduled May 15 has poured cold water on the prospects of an approval coming through. Trevena Inc (NASDAQ: TRVN ) has a tryst with the FDA Friday, with respect to the NDA for its pain drug oleceridine, which was once rejected by the agency on the premise of inadequacy of clinical data.
   U.S. Food and Drug Administration Accepts Karyopharm’s Supplemental New Drug Application for XPOVIO® (selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Line of Therapy  2020/07/20 11:00:00 GlobeNewswire
NEWTON, Mass., July 20, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced…
   Karyopharm sees Q2 Xpovio sales of $18.5M (NASDAQ:KPTI)  2020/07/14 11:43:03 Seeking Alpha
Karyopharm Therapeutics (NASDAQ:KPTI) expects preliminary Q2 net product sales for XPOVIO (selinexor) to be ~$18.5M, (+15% Y/Y), topping Bloomberg average
   Karyopharm Announces Preliminary Unaudited Second Quarter Product Sales for XPOVIO® (selinexor)  2020/07/14 11:00:00 GlobeNewswire
-- Preliminary Unaudited XPOVIO Net Product Sales of Approximately $18.5 Million for the Second Quarter 2020 -- -- Strongest Quarterly XPOVIO Sales Since…

calendar